Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis
: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients. A total of 4...
Gespeichert in:
| Veröffentlicht in: | Gut and liver Jg. 15; H. 3; S. 430 - 439 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Korea (South)
Editorial Office of Gut and Liver
15.05.2021
Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Schlagworte: | |
| ISSN: | 1976-2283, 2005-1212, 2005-1212 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | : The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients.
A total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk.
After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors.
PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. |
|---|---|
| AbstractList | Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients. Methods: A total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk. Results: After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors. Conclusions: PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients. Methods: A total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk. Results: After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors. Conclusions: PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. KCI Citation Count: 0 : The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients. A total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk. After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors. PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. : The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients.Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients.A total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk.MethodsA total of 472 naïve patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk.After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors.ResultsAfter excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51±10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors.PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made.ConclusionsPVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. |
| Author | Yim, Hyung Joon Jung, Young Kul Kim, Yun Soo Kim, Jeong Han Lee, Chan Uk Kwon, Oh Sang Yeon, Jong Eun Suh, Sang Jun Kim, Ju Hyun Shin, Seung Kak |
| AuthorAffiliation | 3 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea 2 Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea 4 Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea 1 Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea |
| AuthorAffiliation_xml | – name: 3 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea – name: 1 Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea – name: 4 Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea – name: 2 Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea |
| Author_xml | – sequence: 1 givenname: Seung Kak orcidid: 0000-0002-5120-5300 surname: Shin fullname: Shin, Seung Kak organization: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea – sequence: 2 givenname: Hyung Joon orcidid: 0000-0002-6036-2754 surname: Yim fullname: Yim, Hyung Joon organization: Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea – sequence: 3 givenname: Jeong Han orcidid: 0000-0002-8383-8524 surname: Kim fullname: Kim, Jeong Han organization: Department of Internal Medicine, Konkuk University School of Medicine, and 4Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea – sequence: 4 givenname: Chan Uk orcidid: 0000-0003-2053-3894 surname: Lee fullname: Lee, Chan Uk – sequence: 5 givenname: Jong Eun orcidid: 0000-0002-0510-7371 surname: Yeon fullname: Yeon, Jong Eun – sequence: 6 givenname: Sang Jun orcidid: 0000-0003-4128-3732 surname: Suh fullname: Suh, Sang Jun organization: Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea – sequence: 7 givenname: Young Kul orcidid: 0000-0002-6566-1382 surname: Jung fullname: Jung, Young Kul organization: Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea – sequence: 8 givenname: Yun Soo orcidid: 0000-0003-2380-1217 surname: Kim fullname: Kim, Yun Soo organization: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea – sequence: 9 givenname: Ju Hyun orcidid: 0000-0001-8981-135X surname: Kim fullname: Kim, Ju Hyun organization: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea – sequence: 10 givenname: Oh Sang orcidid: 0000-0001-9981-3914 surname: Kwon fullname: Kwon, Oh Sang organization: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33115966$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002716890$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNplktFu0zAUhiM0xLqBxBMgX8JFhu3ESXyDNKrBKk1iqgoSV9aJfdx6TeNiu0N7IZ6TpN0Gg6tj2d_5_1_H5yQ76n2PWfaa0TNBqXy_7DtOaV0-yyZDFTnjjB9lEybrKue8KY6zkxhvKK0Yr8WL7LgoGBOyqibZr2sIyUFHvrngO790ejjPMW59H5GATRgIJ98RQiTekos-oYZbF8hihQG2d2TW64AQMZK0QjJ3cT1yl7iF5DV23a6DQKYQtOv9BojryTUkh32K5KdLqwPpkovk45hhF_PzGL12kNCQqQth5aOLL7PnFrqIr-7rafb108Vieplfffk8m55f5bqsecrL1gCzpmGS1kabshClgJJZSbG1rZRlYZAahtYUYAQ3oJvWFqLCChspQRen2buDbh-sWmunPLh9XXq1Dup8vpgpWTdlUzUDOzuwxsON2ga3gXC3b9hf-LBU42x1h8rWBTey4kO4uiwsbxmtmWa2sqwEJqtB68NBa7trN2j0MJ8A3RPRpy-9Ww2ZblXDuKzEGObtvUDwP3YYk9q4OM4fevS7qHgpRFMOrmJA3_zt9WjysBR_tHTwMQa0jwijatw39bBvA3r2D6pdGv7Tjyld93_Db7T72tU |
| CitedBy_id | crossref_primary_10_1186_s12876_022_02541_1 crossref_primary_10_1128_aac_01827_24 crossref_primary_10_3748_wjg_v28_i41_5910 crossref_primary_10_1016_j_jhep_2022_07_018 crossref_primary_10_3350_cmh_2024_0506 |
| Cites_doi | 10.1111/j.1478-3231.2009.02192.x 10.1001/jamaoncol.2018.4070 10.1038/ajg.2014.145 10.1186/1471-230X-12-14 10.1002/hep.28916 10.7150/jca.16523 10.1016/j.jhep.2017.03.021 10.1111/liv.13489 10.1002/hep.27727 10.1111/jgh.13020 10.1053/j.gastro.2011.06.036 10.1002/hep.29800 10.1007/s10620-016-4431-8 10.1038/ajg.2017.254 10.1007/s10620-012-2402-2 10.1016/j.jhep.2018.05.009 10.1007/s12072-015-9675-4 10.1111/jgh.13473 10.1016/j.cgh.2018.09.010 10.1002/hep.27654 10.1007/s00535-011-0522-7 10.1002/hep.26180 10.1111/jvh.12368 10.1001/jama.295.1.65 10.1002/hep.23327 |
| ContentType | Journal Article |
| Copyright | Copyright © Gut and Liver. 2021 |
| Copyright_xml | – notice: Copyright © Gut and Liver. 2021 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA ACYCR |
| DOI | 10.5009/gnl20074 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-1212 |
| EndPage | 439 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9784868 oai_doaj_org_article_f732d962a1f743f2b1071c1f6f14a196 PMC8129658 33115966 10_5009_gnl20074 |
| Genre | Journal Article |
| GroupedDBID | --- 5-W 8JR AAKDD AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P GROUPED_DOAJ GX1 HYE HZB OK1 RPM 9ZL NPM 7X8 5PM 53G 85H M~E |
| ID | FETCH-LOGICAL-c472t-4bda1fd81907dcd43545a41f90ebfb9943de0d1efd3ad52dac8bf356e6e899ac3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 7 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000652440500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1976-2283 2005-1212 |
| IngestDate | Tue Nov 21 21:37:49 EST 2023 Fri Oct 03 12:51:39 EDT 2025 Tue Nov 04 01:59:41 EST 2025 Thu Oct 02 06:01:06 EDT 2025 Thu Apr 03 06:57:27 EDT 2025 Sat Nov 29 01:46:43 EST 2025 Tue Nov 18 22:37:22 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Partial virological response Hepatocellular carcinoma Hepatitis B virus Liver cirrhosis Entecavir |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c472t-4bda1fd81907dcd43545a41f90ebfb9943de0d1efd3ad52dac8bf356e6e899ac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Seung Kak Shin and Hyung Joon Yim contributed equally to this work as first authors. |
| ORCID | 0000-0002-8383-8524 0000-0002-6566-1382 0000-0002-6036-2754 0000-0001-9981-3914 0000-0003-2053-3894 0000-0002-0510-7371 0000-0003-4128-3732 0000-0003-2380-1217 0000-0002-5120-5300 0000-0001-8981-135X |
| OpenAccessLink | https://doaj.org/article/f732d962a1f743f2b1071c1f6f14a196 |
| PMID | 33115966 |
| PQID | 2455840715 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9784868 doaj_primary_oai_doaj_org_article_f732d962a1f743f2b1071c1f6f14a196 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8129658 proquest_miscellaneous_2455840715 pubmed_primary_33115966 crossref_primary_10_5009_gnl20074 crossref_citationtrail_10_5009_gnl20074 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-May-15 |
| PublicationDateYYYYMMDD | 2021-05-15 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-May-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Gut and liver |
| PublicationTitleAlternate | Gut Liver |
| PublicationYear | 2021 |
| Publisher | Editorial Office of Gut and Liver Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Publisher_xml | – name: Editorial Office of Gut and Liver – name: Gastroenterology Council for Gut and Liver – name: 거트앤리버 소화기연관학회협의회 |
| References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref25 ref20 ref22 ref21 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref20 doi: 10.1111/j.1478-3231.2009.02192.x – ident: ref24 doi: 10.1001/jamaoncol.2018.4070 – ident: ref3 doi: 10.1038/ajg.2014.145 – ident: ref21 doi: 10.1186/1471-230X-12-14 – ident: ref2 doi: 10.1002/hep.28916 – ident: ref18 doi: 10.7150/jca.16523 – ident: ref5 doi: 10.1016/j.jhep.2017.03.021 – ident: ref16 doi: 10.1111/liv.13489 – ident: ref25 doi: 10.1002/hep.27727 – ident: ref9 doi: 10.1111/jgh.13020 – ident: ref10 doi: 10.1053/j.gastro.2011.06.036 – ident: ref8 doi: 10.1002/hep.29800 – ident: ref7 doi: 10.1007/s10620-016-4431-8 – ident: ref17 doi: 10.1038/ajg.2017.254 – ident: ref23 doi: 10.1007/s10620-012-2402-2 – ident: ref6 doi: 10.1016/j.jhep.2018.05.009 – ident: ref12 doi: 10.1007/s12072-015-9675-4 – ident: ref19 doi: 10.1111/jgh.13473 – ident: ref4 doi: 10.1016/j.cgh.2018.09.010 – ident: ref15 doi: 10.1002/hep.27654 – ident: ref11 doi: 10.1007/s00535-011-0522-7 – ident: ref14 doi: 10.1002/hep.26180 – ident: ref22 doi: 10.1111/jvh.12368 – ident: ref1 doi: 10.1001/jama.295.1.65 – ident: ref13 doi: 10.1002/hep.23327 |
| SSID | ssj0061275 |
| Score | 2.300017 |
| Snippet | : The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether... Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 430 |
| SubjectTerms | entecavir hepatitis b virus hepatocellular carcinoma liver cirrhosis Original partial virological response 내과학 |
| Title | Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33115966 https://www.proquest.com/docview/2455840715 https://pubmed.ncbi.nlm.nih.gov/PMC8129658 https://doaj.org/article/f732d962a1f743f2b1071c1f6f14a196 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002716890 |
| Volume | 15 |
| WOSCitedRecordID | wos000652440500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Gut and Liver, 2021, 15(3), , pp.430-439 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 2005-1212 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061275 issn: 1976-2283 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9tAEF3aUEovpelX1KZhUwo9iVjS7ko6JqYhhTaYkAb3tOxnIpxKRbLzk_I7M6OVTBwCvfRksMZmpXmaebMavSHkC9MOX9dM4kJMTMychjgoBI81Jj-vEmf6Df2LH_npaTGfl7N7o76wJyzIA4cLd-DzLLWlSFXiIdn5VEO9kpjEC58wBfDB6AusZyymQgwWKFveP0_ORYwCL0F2lgOhOLisr3F_jm0kol6vH9JL3frHqObDjsl7Kej4FXk5cEd6GNa8TZ64-jV5_nN4Ov6G3M7wdMDiomrHmEbPQhOso_00cJrS34DtjjaeYj-AUTdVS8-DtACFYIE96q6jQAvpWdUt0O4EMtaywR1-bFmlU5w-VDd_FK1qOguyrB3F_dxgiSJJ9AjXsOri0fvO0mnVtldNV3Vvya_jb-fTk3iYwxAblqfLmGkLV98id8itsUCwGFcs8eXEaa_LkmXWTWzivM2U5alVptA-48IJB9WcMtk7slU3tdshVKnUFznTxk8cY5lRNjMWOJQ2zHOvioh8HZ0izSBSjrMyriUUK-g-ObovIvtry79BmOMRmyP06_o4Smn3XwDA5AAw-S-AReQzoEIuTNX_Hj8vG7loJRQc3yUU4awQsO79ETQS7k90iapds-pkyjhwPPhLHpH3AUTr9WQodQT1ZkTyDXhtLHjzSF1d9RrgwMtQtufD_zjDj-RFip06qEnLd8nWsl25T-SZuQG8tHvkaT4v9vrb6w6PcCyP |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Partial+Virological+Response+after+2+Years+of+Entecavir+Therapy+Increases+the+Risk+of+Hepatocellular+Carcinoma+in+Patients+with+Hepatitis+B+Virus-Associated+Cirrhosis&rft.jtitle=Gut+and+liver&rft.au=Shin%2C+Seung+Kak&rft.au=Yim%2C+Hyung+Joon&rft.au=Kim%2C+Jeong+Han&rft.au=Lee%2C+Chan+Uk&rft.date=2021-05-15&rft.eissn=2005-1212&rft.volume=15&rft.issue=3&rft.spage=430&rft_id=info:doi/10.5009%2Fgnl20074&rft_id=info%3Apmid%2F33115966&rft.externalDocID=33115966 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-2283&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-2283&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-2283&client=summon |